What percentage of opioid-related overdose deaths in 2017 involved prescription opioids?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Opioid Overdose Deaths in 2017

Of the nearly 47,000 opioid-related overdose deaths in 2017, approximately 17% involved prescription opioids only, while the majority (58.7%) involved illicit opioids only, and 18.5% involved both prescription and illicit opioids. 1

Breakdown of the 47,600 Opioid Deaths

The specific numbers translate to approximately:

  • 8,250 deaths (17.4%) involved prescription opioids exclusively 1
  • 27,900 deaths (58.7%) involved illicit opioids only (primarily heroin and illicitly manufactured fentanyl) 1
  • 8,800 deaths (18.5%) involved both prescription and illicit opioids 1
  • 2,650 deaths (5.5%) could not be classified by opioid type 1

Critical Context About the Shifting Epidemic

The 2017 data represents a pivotal transition point where illicitly manufactured fentanyl (IMF) overtook prescription opioids as the primary driver of opioid mortality. 2 From 2013 to 2017, drug overdose death rates increased 90%, driven primarily by synthetic opioids (predominantly IMF and fentanyl analogs), not prescription medications. 3

The Three-Wave Pattern

The opioid epidemic evolved through distinct phases:

  • Wave 1 (1990s-2010): Prescription opioid deaths peaked at over 11,000 annually by 2012, when 255 million opioid prescriptions were written 4
  • Wave 2 (2010-2013): Heroin deaths escalated as users transitioned from prescription opioids, reaching 14,495 deaths in 2017 4
  • Wave 3 (2013-present): Synthetic opioid deaths surged due to IMF contamination of the illicit drug supply 2, 4

Important Clinical Implications

By 2017, two-thirds of all drug overdose deaths (67.8%) involved an opioid, but the nature of these deaths had fundamentally changed from prescription-driven to illicit fentanyl-driven mortality. 2 This distinction is critical because:

  • Prescription opioid deaths began declining after 2017 3, 5
  • Synthetic opioid deaths continued increasing by 10% from 2017 to 2018 despite overall opioid death decreases 5
  • IMF was involved in approximately two-thirds of all opioid deaths by early 2018 3

Polysubstance Involvement

A critical finding often overlooked: 62.6% of all opioid deaths in 2018 co-occurred with at least one common nonopioid drug, with benzodiazepines present in 31-61% of fatal opioid overdoses. 6, 3 This polysubstance pattern substantially increases mortality risk, with benzodiazepine co-involvement increasing death rates 3- to 10-fold compared to opioids alone. 6

Geographic and Demographic Patterns

The hardest-hit states in 2017 were concentrated in Appalachia and the Northeast, with West Virginia (51.5 per 100,000), Delaware (43.8 per 100,000), and Maryland (37.2 per 100,000) experiencing the highest age-adjusted death rates. 7 The epidemic disproportionately affected individuals aged 25-54 years, with opioids causing 20% of all deaths in the 24-35 age group. 7

References

Research

Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017.

MMWR. Morbidity and mortality weekly report, 2018

Research

The Opioid Crisis: Prevalence and Markets of Opioids.

Forensic science review, 2022

Research

Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018.

MMWR. Morbidity and mortality weekly report, 2020

Guideline

Benzodiazepine and Opioid Co-Prescribing Risks

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.